You need to profile your AAV vector to ensure you are developing an effective gene therapy delivery system. In this mini-guide, learn about 4 technologies that give you a full stability profile of your gene therapy vector. From serotype assessment, to monitoring aggregate formation, to checking vector purity, to evaluating capsid assembly and genetic fill — these 4 technologies will help you identify the best formulation and multi-parameter quality control of AAVs, so you build more effective gene therapy vectors.
Ready to tackle your challenging stability characterizations?
Discover toolsSee more related content

Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab

With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...

SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...

Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.

The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi

Learn what attributes Prometheus users considered a must-have and how we made sure to preserve them when integrating and implementing new biophysical techniques. Prometheus Panta gives you the ability


Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres

Reproducibility is a key tenet of scientific research, but many pharma groups have projects that collaborate across different sites or that rely on materials prepared by other specialist...